Triple negative breast cancer (TNBC), ER-/PR-/HER2-, accounts for 10–20% of BC and it is characterized by high aggressiveness and poor prognosis owing to the lack of targeted therapeutic strategies (6, 7). This evidence concerns the gene ERBB2 and breast cancer.